Current perspectives of 14C-isotope measurement in biomedical accelerator mass spectrometry

Analytical and Bioanalytical Chemistry

Volumn 378, Issue 2, 2004, Pages 356-364

  Lappin, Graham ^a   Garner, R Colin ^a  

^a Xceleron Ltd   (United Kingdom)

Author keywords

Accelerator mass spectrometry; Biomarkers; Microdosing; Phase 0; Ultrasensitive drug analysis

Indexed keywords

BIOMARKERS; DNA; DRUG PRODUCTS; ISOTOPES; MASS SPECTROMETRY; MEDICAL APPLICATIONS; METABOLISM; NUCLEAR PHYSICS; PROTEINS; TOXICITY; TUMORS; VAN DE GRAAFF ACCELERATORS;

ACCELERATOR MASS SPECTROMETRY; MICRODOSING; PHASE 0; ULTRASENSITIVE DRUG ANALYSIS;

CARBON;

ANIMALIA;

EID: 6944233468     PISSN: 16182642     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00216-003-2348-5     Document Type: Review

References (63)

1. Bennett CL, Beukens RP, Glover MR, Gove HE, Liebert RB, Litherland AE, Purser KH, Sondheim WE (1977) Science 198:508
2. Nelson DE, Korteling RG, Stott WR (1977) Science 198:507
3. Buchholz BA, Arjomand A, Dueker SR, Schneider PD, Clifford AJ, Vogel JS (1999) Anal Biochem 269:348-352
4. L'Annunziata MF, Kessler MJ (1998) Radiotracer liquid scintillation analysis. In: L'Annunziata MF (ed) Handbook of radioactivity analysis. Academic Press, New York
5. Vogel JS, Turteltaub KW, Finkel R (1995) Anal Chem 67: 353A-359A
6. Barker J, Garner RC (1999) Rapid Commun Mass Spectrom 13: 285-293
7. Turteltaub KW, Vogel JS (2000) Curr Pharm Des 6:991-1007
8. Lappin G, Garner RC (2003) Ultra-sensitive detection of radiolabelled drugs and their metabolites using accelerator mass spectrometry. In: Smith RM, Wilson ID (eds) Handbook of analytical separations. Elsevier, Amsterdam
9. Turteltaub K.W, Felton JS, Gledhill BL, Vogel JS, Southon JR, Caffee MW, Finkel RC, Nelson DE, Proctor ID, Davis JC (1990) Proc Natl Acad Sci USA 87:5288-5292
10. Felton JS, Turteltaub KW (1994) Environ Health Perspect 102: 450-452
11. Lappin G, Garner RC (2003) Nat Rev (Drug Discovery) 2: 233-240
12. Committee for Proprietary Medicinal Products (2003) Position paper on non-clinical safety studies to support clinical trials with a single microdose. CPMP/SWP/2599/02
13. Vogel JS (1992) Radiocarbon 34:344-350
14. Mucciarone DA, Dunbar RB (1992) J Sed Petrol 62:731-733
15. Hotchkis M, Fink D, Tuniz C, Vogt S (2000) Appl Radiat Isot 53:31-37
16. International Commission on Radiological Protection in Biomedical Research (1992) ICRP Publication 62 Ann ICRP 22(3):1-18
17. Dolphin GW, Eve IS (1966) Health Phys 12:163-172
18. Turteltaub KW, Vogel JS, Frantz CE, Shen N (1992) Cancer Res 52:4682-4687
19. Frantz CE, Bangerter C, Fultz E, Mayer KM, Vogel JS, Turteltaub KW (1995) Carcinogenesis 16:367-373
20. Turteltaub KW, Mauthe RJ, Dingley KH, Vogel JS, Frantz CE, Gamer RC, Shen N (1997) Mutation Res 376:243-252
21. Mauthe RJ, Dingley KH, Leveson SH, Freeman PHT, Turesky RJ, Gamer RC, Turteltaub KW (1999) Int J Cancer 80:539-545
22. Turteltaub KW, Dingley KH, Curtis KD, Malfatti MA, Turesky RJ, Garner RC, Felton JS, Lang NP (1999) Cancer Lett 143: 149-155
23. Gamer RC, Lightfoot TJ, Cupid BC, Russell D, Coxhead JM, Kutschera W, Priller A, Rom W, Steier P, Alexander DJ, Leveson SH, Dingley KH, Mauthe RJ, Turteltaub KW (1999) Cancer Lett 143:161-165
24. Lightfoot TJ, Coxhead JM, Cupid BC, Nicholson S, Garner RC (2000) Mutation Res 472:119-127
25. Creek MR, Mani C, Vogel JS, Turteltaub KW (1997) Carcinogenesis 18:2421-2427
26. Mani C, Freeman S, Nelson DO, Vogel JS, Turteltaub KW (1999) Toxicol Appl Pharmacol 159:83-90
27. Williams KE, Carver TA, Miranda JJL, Kautianen A, Vogel JS, Dingley K, Baldwin MA, Turteltaub KW, Burlingame AL (2002) Mol Cell Proteomics 1:885-895
28. Kwok ESC, Bucholz BA, Vogel JS, Turteltaub KW, Eastmond DA (1999) Toxicol Appl Pharmacol 159:18-24
29. White INH, Martin EA, Mauthe RJ, Vogel JS, Turteltaub KW, Smith LL (1997) Chem Biol Interact 106:149-160
30. Li XS, Wang HF, Shi JY, Wang XY, Liu YF, Li K, Lu XY, Wang JJ, Liu KX, Guo, Z Y (1996) Radiocarbon 38:347-353
31. Shi J, Wang H, Wu X, Li X, Liu Y, Li K, Lu X, Wang J, Liu K (1997) Chin Sci Bull 42:1662-1664
32. Kautiainen A, Vogel JS, Turteltaub KW (1997) Chem Biol Interact 106:109-121
33. Vogel JS, Turteltaub KW (1998) In: Müller C (ed) Mathematical modeling in experimental nutrition. Plenum, New York
34. Stenström K, Leide-Svegbom S, Erlandsson B, Hellborg R, Mattsson S, Nilsson L-E, Nosslin B, Skog G, Wiebert A (1996) Appl Radiat Isot 47:4176-4220
35. Clifford AJ, Arjomand A, Dueker SR, Schneider PD, Buchholz BA, Vogel JS (1998) In: Müller C (ed) Mathematical modeling in experimental nutrition. Plenum, New York
36. Dueker SR, Lin Y, Buchholz BA, Schneider PD, Lame MW, Segall HJ, Vogel JS, Clifford AJ (2000) J Lipid Res 41:17901800
37. Svegborn SL, Stenström K, Olofsson M, Mattsson S, Nilsson L-E, Nosslin B, Pau K, Johansson L, Erlansson B, Hellborg R, Skog G (1999) Eur J Nucl Med 26:573-580
38. Gunnarsson M, Svegbom SL, Stenström K, Skog G, Nilsson L-E, Hellborg R, Mattsson S (2002) Br J Radiol 75:982-986 39.
39. Bortz JT, Wertz PW, Downing DT (1989) J Invest Dermatol 93:723-727
40. Williams ML, Vogel JS, Ghadially R, Brown BE, Elia PM (1992) Arch Dermatol 128:1065-1071
41. Bogen KT, Keating GA, Meissner S, Vogel JS (1998) J Exposure Anal Environ Epidemiol 8:253-271
42. Oilman SD, Gee SJ, Hammock BD, Vogel JS, Haak K, Buchholz A, Freeman SPHT, Wester RC, Hui X, Maibach HI (1998) Anal Chem 70:3463-3469
43. Buchholz BA, Fultz E, Haack KW, Vogel JS, Gilman SD, Gee SG, Hammock BD, Hui X, Wester RC, Maibach HI (1999) Anal Chem 71:3519-3525
44. Buchholz BA, Pawley NH, Vogel JS, Mauthe RJ (1997) J Appl Toxicol 17:231-234
45. Gamer RC, Barker J, Flavell C, Gamer JV, Whattam M, Young GC, Cussans N, Jezequel S, Leong D (2000) J Pharm Biomed Anal 24:197-209
46. Gamer RC, Leong D (2000) Nucl Instrum Methods Phys Res B 172:892-898
47. Kaye B, Gamer RC, Mauthe RJ, Freeman SPHT, Turteltaub KW (1997) J Pharm Biomed Anal 16:541-543
48. Garner RC (2000) Current Drug Metab 1:205-213
49. Garner RC (2001) In: Pleiss U, Voges R (eds) Synthesis and applications of isotopically labelled compounds, vol 7. Wiley
50. Gamer RC (1999) European Pharmaceutical Contractor Technomark Consulting Services, November 1999, pp 22-28
51. Cupid BC, Garner RC (1998) In: Gooderman N (ed) Drug metabolism: towards the next millennium. IOS Press
52. Vogel JS, Turteltaub KW (1994) Nucl Instrum Methods Phys Res B 92:445-453
53. Fifield LK (1999) Rep Prog Phys 62:1223-1274
54. Young G, Ellis W, Ayrton J, Hussey E, Adamkiewicz B (2001) Xenobiotica 31:619-632
55. Gamer RC, Garner JV, Gregory S, Whattam M, Calam A, Leong D (2002) J Phann Sci 91:32-40
56. Garner RC, Goris I, Laenen AAE, Vanhoutte E, Meuldermans W, Gregory S, Garner JV, Leong D, Whattam Calam A, Snel CAW (2002) Drug Metab Dispos 30:823-830
57. Dingley KH, Roberts ML, Velsko CA, Turteltaub KW (1998) Chem Res Toxicol 11:1217-1222
58. Faarinen M, Magnusson C-E, Hellborg R, Mattsson S, Kiisk M, Persson P, Schütz A, Skog G, Stenström K (2001) J Inorg Biochem 87:57-61
59. Synal H-A, Beer J, Bonani G, Lukasczyk Ch, Suter M (1994) Nucl Instrum Methods Phys Res B 92:79-84
60. Popplewell JF, King SJ, Day JP, Ackrill P, Fifield LK, Cresswell RG, di Tada ML, Liu K (1998) J Inorg Biochem 69:177-180
61. Zafar TA, Weaver CM, Martin BR, Flarend R, Elmore D (1997) Proc Soc Exp Biol Med 216: 81-85
62. Dittrich-Hannen B, Ames F, Suter M, Wagner MJM, Schnabel Ch, Michel R, Herpers U, Günther E (1996) Nucl Instrum Methods Phys Res B 113:453-456
63. Bhattacharyya MH, Sacco-Gibson N, Peterson DP (1990) Nucl Instrum Methods Phys Res B 52:531-535